Weekly AI/ML & Biotech Digest — Aug 24 to Aug 30, 2026
Curated weekly digest of notable AI/ML and biotech developments. Flagged items are manually selected; remaining items are the week's most recent.
🧬 Biotech
- ★ Roche pens $2.5 billion pact for Hanmi's muscle-conserving obesity drug — Roche has entered a $2.5 billion deal to license Hanmi's early-stage muscle-conserving obesity asset, betting on a novel approach to weight loss that preserves muscle mass. (morning-news-biotech, 2026-08-26)
- ★ CRISPR Therapeutics reports Durability of Effects of CTX310 gene therapy at ESC Congress — CRISPR Therapeutics presented late-breaking abstract on CTX310, a CRISPR-Cas9 gene therapy targeting ANGPTL3 for familial hypercholesterolemia, with clinical update planned for August. (morning-news-biotech, 2026-08-26)
- ★ Ultrafast and reference-free sequence discovery in single-cell data — Abstract Knowledge of RNA sequences, expression, splicing, isoforms, structure and modifications is central for understanding and targeting cellular processes.
- ★ Virtual Cell Challenge 2026: Benchmarking zero-shot generalization across cellular contexts — The Virtual Cell Challenge returns in 2026 with a more demanding test of biological generalization: zero-shot prediction across multiple independent cellular contexts.
🤖 AI/ML
- ★ OpenAI is building AI agents for everything. Will everyone use them? — OpenAI's ChatGPT Work product demonstrates 98% internal adoption but only 17% organizational uptake, revealing a product-market fit challenge for non-engineers in AI agent adoption. (morning-news-aiml, 2026-08-25)
- ★ Google DeepMind leadership shakeup: Demis Hassabis becomes Chair, Jeff Dean departs — Google DeepMind CEO Demis Hassabis steps up to become Chair of DeepMind and Alphabet's Chief Scientist, while Jeff Dean and Sanjay Ghemawat leave to form Discovery Loop, a new AI-focused public benefit corporation. (morning-news-aiml, 2026-08-25)
- ★ TrueForge open-source AI agent harness is 30-75% cheaper — TrueFoundry's MIT-licensed TrueForge harness delivers significant cost savings over Claude Managed Agents through context compaction and sandbox optimization. (morning-news-aiml, 2026-08-29)
- ★ Nvidia just showed that the harness, not the AI model, is now the real hero — Nvidia's research demonstrates that for long-horizon AI tasks, the harness (scaffolding, tools, memory management around the model) is more critical than the underlying model — a supervisor component helped Claude Opus 5 achieve 100% on the ARC-AGI-3 benchmark versus 30% without it. (morning-news-aiml, 2026-08-30)
- ★ LTX-2.5 can generate a 10-second AI video from an image in just 6.8 seconds on NVIDIA superchips and its open weights — LTX-2.5, an open-weights video and world model from LTX (spun out of Lightricks), generates a 10-second 720p clip in 6.8 seconds on dual NVIDIA GB200 superchips — about 7x faster than rivals — and won 67% of blind quality tests against Gemini Omni Flash, Seedance 2.5, and FLUX 3. (morning-news-aiml, 2026-08-30)
💊 FDA / Catalysts
- ★ Lisraya (Brepocitinib) — FDA Approved — Roivant's JAK inhibitor approved for dermatomyositis; potential blockbuster therapy. (fda-biotech-weekly, 2026-08-27)
Comments
Post a Comment